Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Mar 8, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a new testing method called metagenomic deep sequencing (MDS) to diagnose and manage intraocular infections, which are infections inside the eye. The trial will compare MDS to standard testing methods to see if using MDS helps patients get the right treatment faster and improves their overall health outcomes. Patients who have certain types of eye infections, like uveitis or post-operative endophthalmitis, and are 18 years or older may be eligible to participate.
If you join the trial, you will receive standard care for your eye condition, and some patients will also receive results from the new MDS test. You'll be followed up at specific times after your initial visit to assess how well the treatments are working and your quality of life. The trial is currently looking for participants, and it’s important to note that you cannot participate if you are under 18, pregnant, or if there isn’t enough sample for the MDS test. By participating, you could help improve how these eye infections are diagnosed and treated for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presumed infectious anterior uveitis, or intermediate uveitis, or posterior uveitis, or panuveitis
- • Presumed post-operative endophthalmitis
- • Unilateral or bilateral
- • 18 years and older
- Exclusion Criteria:
- • Insufficient specimen for MDS
- • Age \< 18 years of age
- • Pregnancy
- • Unable to consent
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Thuy Doan, MD, PhD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials